These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

583 related articles for article (PubMed ID: 31209849)

  • 1. Human Microbiota and Personalized Cancer Treatments: Role of Commensal Microbes in Treatment Outcomes for Cancer Patients.
    Gately S
    Cancer Treat Res; 2019; 178():253-264. PubMed ID: 31209849
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of tumor and gut microbiotas on cancer therapy: Beneficial or detrimental?
    Hekmatshoar Y; Rahbar Saadat Y; Hosseiniyan Khatibi SM; Ozkan T; Zununi Vahed F; Nariman-Saleh-Fam Z; Pourghassem Gargari B; Sunguroglu A; Zununi Vahed S
    Life Sci; 2019 Sep; 233():116680. PubMed ID: 31344431
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integration of microbiome and epigenome to decipher the pathogenesis of autoimmune diseases.
    Chen B; Sun L; Zhang X
    J Autoimmun; 2017 Sep; 83():31-42. PubMed ID: 28342734
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current understanding of microbiota- and dietary-therapies for treating inflammatory bowel disease.
    Eom T; Kim YS; Choi CH; Sadowsky MJ; Unno T
    J Microbiol; 2018 Mar; 56(3):189-198. PubMed ID: 29492876
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Microbiota: a key orchestrator of cancer therapy.
    Roy S; Trinchieri G
    Nat Rev Cancer; 2017 May; 17(5):271-285. PubMed ID: 28303904
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The potential impact of gut microbiota on your health:Current status and future challenges.
    Sirisinha S
    Asian Pac J Allergy Immunol; 2016 Dec; 34(4):249-264. PubMed ID: 28042926
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunomodulatory potential of gut microbiome-derived short-chain fatty acids (SCFAs).
    Ratajczak W; Rył A; Mizerski A; Walczakiewicz K; Sipak O; Laszczyńska M
    Acta Biochim Pol; 2019 Mar; 66(1):1-12. PubMed ID: 30831575
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fine-Tuning Cancer Immunotherapy: Optimizing the Gut Microbiome.
    Pitt JM; Vétizou M; Waldschmitt N; Kroemer G; Chamaillard M; Boneca IG; Zitvogel L
    Cancer Res; 2016 Aug; 76(16):4602-7. PubMed ID: 27474734
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modulation of cancer immunotherapy efficacy by gut microbiota.
    Huo S; Liu L; Liu J; Li Q; Wang J
    Discov Med; 2019 Feb; 27(147):93-100. PubMed ID: 30939293
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Understanding the microbiome: Emerging biomarkers for exploiting the microbiota for personalized medicine against cancer.
    Rajpoot M; Sharma AK; Sharma A; Gupta GK
    Semin Cancer Biol; 2018 Oct; 52(Pt 1):1-8. PubMed ID: 29425888
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The role of intestinal microbiota in the response to anti-tumor therapies].
    Vétizou M; Daillère R; Zitvogel L
    Med Sci (Paris); 2016 Nov; 32(11):974-982. PubMed ID: 28008838
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The microbiome and cancer for clinicians.
    Picardo SL; Coburn B; Hansen AR
    Crit Rev Oncol Hematol; 2019 Sep; 141():1-12. PubMed ID: 31202124
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Influence of the Gut Microbiome on Cancer, Immunity, and Cancer Immunotherapy.
    Gopalakrishnan V; Helmink BA; Spencer CN; Reuben A; Wargo JA
    Cancer Cell; 2018 Apr; 33(4):570-580. PubMed ID: 29634945
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The microbiome, cancer, and cancer therapy.
    Helmink BA; Khan MAW; Hermann A; Gopalakrishnan V; Wargo JA
    Nat Med; 2019 Mar; 25(3):377-388. PubMed ID: 30842679
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gut Microbiota as a Positive Potential Therapeutic Factor in Carcinogenesis: an Overview of Microbiota-Targeted Therapy.
    Joukar F; Mavaddati S; Mansour-Ghanaei F; Samadani AA
    J Gastrointest Cancer; 2020 Jun; 51(2):363-378. PubMed ID: 31025167
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gut microbiome and response to checkpoint inhibitors in non-small cell lung cancer-A review.
    Nagasaka M; Sexton R; Alhasan R; Rahman S; Azmi AS; Sukari A
    Crit Rev Oncol Hematol; 2020 Jan; 145():102841. PubMed ID: 31884204
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted modulation of gut and intra-tumor microbiota to improve the quality of immune checkpoint inhibitor responses.
    Wang W; Fan J; Zhang C; Huang Y; Chen Y; Fu S; Wu J
    Microbiol Res; 2024 May; 282():127668. PubMed ID: 38430889
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Impact of Intratumoral and Gastrointestinal Microbiota on Systemic Cancer Therapy.
    Cogdill AP; Gaudreau PO; Arora R; Gopalakrishnan V; Wargo JA
    Trends Immunol; 2018 Nov; 39(11):900-920. PubMed ID: 30392721
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular Paths Linking Metabolic Diseases, Gut Microbiota Dysbiosis and Enterobacteria Infections.
    Serino M
    J Mol Biol; 2018 Mar; 430(5):581-590. PubMed ID: 29374557
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gut microbiota and host metabolism in liver cirrhosis.
    Usami M; Miyoshi M; Yamashita H
    World J Gastroenterol; 2015 Nov; 21(41):11597-608. PubMed ID: 26556989
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.